Needham & Company LLC Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price
Lucid Diagnostics (NASDAQ:LUCD – Free Report) had its price objective boosted by Needham & Company LLC from $2.50 to $3.00 in a report published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, Ascendiant Capital Markets reduced their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and […]
Lucid Diagnostics (NASDAQ:LUCD – Free Report) had its price objective boosted by Needham & Company LLC from $2.50 to $3.00 in a report published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, Ascendiant Capital Markets reduced their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and […]
